Sourcing Guide Contents
Industrial Clusters: Where to Source Breo Ellipta Manufacturer Assistance Program
SourcifyChina Sourcing Intelligence Report: Market Analysis for Pharmaceutical Support Programs (Clarification & Strategic Guidance)
Date: January 15, 2026
Prepared For: Global Procurement Managers
Subject: Critical Clarification & Strategic Sourcing Path for “Breo Ellipta Manufacturer Assistance Program” in China
Executive Summary
This report addresses a critical misconception: “Breo Ellipta” is a globally patented prescription pharmaceutical product (fluticasone furoate/vilanterol inhaler) exclusively manufactured and distributed by AstraZeneca under stringent FDA/EMA regulatory oversight. China does not have authorized manufacturers producing Breo Ellipta or its associated “Manufacturer Assistance Program” (MAP). MAPs are patient support services managed directly by the originator pharmaceutical company, not outsourced manufacturing commodities. Attempting to source this specific program from Chinese manufacturers is legally impossible, high-risk, and violates international IP laws. This report clarifies realities, outlines legitimate Chinese pharmaceutical manufacturing capabilities, and provides actionable guidance for procurement professionals.
Critical Market Reality Check: Why “Breo Ellipta MAP Sourcing” is Not Feasible
- Intellectual Property & Regulatory Barrier:
- Breo Ellipta is protected by robust patents (expiring ~2029-2031 in major markets). Manufacturing requires AstraZeneca licensing, which is not granted for active pharmaceutical ingredients (APIs) or finished dosage forms (FDFs) in China for this product.
- Chinese manufacturers cannot legally produce branded, patented drugs like Breo Ellipta. “Manufacturer Assistance Programs” are intrinsically tied to the originator brand and its regulatory dossier.
- Nature of MAPs:
- MAPs are patient services (copay assistance, free drug programs for uninsured, adherence support), not physical goods. They are administered by the brand owner’s specialty pharmacies or dedicated patient services hubs (e.g., in the US/EU), not outsourced to third-party manufacturers in China.
- China’s Pharmaceutical Regulatory Framework:
- NMPA (China’s FDA) strictly regulates drug manufacturing. Facilities producing generic equivalents post-patent expiry require extensive NMPA approval and cannot mimic originator MAPs. Production of patented drugs is prohibited.
- High Risk of Counterfeits:
- Any entity in China claiming to supply “Breo Ellipta” or its MAP is offering counterfeit goods, posing severe legal, reputational, and patient safety risks. SourcifyChina strongly advises against engagement.
Legitimate Sourcing Pathways: Where China Does Play a Role in Pharma Supply Chains
While Breo Ellipta MAP sourcing is impossible, China is a global powerhouse in specific, legitimate segments of the pharmaceutical supply chain. Procurement managers should focus efforts here:
| Supply Chain Segment | Key Chinese Industrial Clusters | Primary Capabilities | Relevance to Global Pharma |
|---|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | Jiangsu Province (Lianyungang, Changzhou), Shandong Province (Weifang), Zhejiang Province (Hangzhou, Taizhou) | Production of generic, off-patent APIs (e.g., Paracetamol, Aspirin, Metformin APIs). Increasing complexity in complex synthetics & biologics intermediates. | Critical source for generic drug manufacturers globally. Requires rigorous quality audits (cGMP). |
| Generic Finished Dosage Forms (FDFs) | Jiangsu (Suzhou, Wuxi), Shanghai, Tianjin, Hubei (Wuhan) | Tablets, capsules, injectables (primarily for domestic market & emerging economies). Limited EMA/FDA-approved facilities. | Growing source for generic drugs in non-IP-sensitive markets. Not applicable to originator brands like Breo Ellipta. |
| Pharmaceutical Excipients | Shandong, Zhejiang, Hebei | Production of lactose, starches, cellulose derivatives, PEGs. | Essential raw materials for global drug formulation. Generally lower IP risk, higher volume. |
| Medical Devices (Inhalers) | Guangdong (Shenzhen, Dongguan), Zhejiang (Ningbo, Hangzhou) | Device Components Only (plastic housings, actuators, caps). NOT drug-containing inhalers for regulated markets. | Potential supplier for non-sterile device components under strict OEM agreements with originators. Drug fill & finish remains with originator. |
⚠️ Critical Distinction: Chinese manufacturers may produce generic inhaler devices (post-patent) or components under license, but NEVER the drug-device combination product (like Breo Ellipta) for regulated markets during patent life. MAPs remain solely with AstraZeneca.
Strategic Recommendation: Redirecting Sourcing Efforts
- Abandon “Breo Ellipta MAP” Sourcing: Treat any such offer as a high-risk counterfeit operation.
- Engage AstraZeneca Directly: For MAP access or patient support services, contact AstraZeneca’s official global or regional patient services division.
- Explore Legitimate Chinese Pharma Sourcing (If Applicable):
- For Generic APIs/FDFs: Target Jiangsu, Shandong, or Zhejiang clusters. Prioritize NMPA-certified sites with FDA/EMA cGMP compliance (e.g., Jiangsu Hengrui Medicine, Shandong Qilu Pharmaceutical).
- For Inhaler Device Components: Focus on Guangdong (Shenzhen/Dongguan) for precision manufacturing. Require full traceability, ISO 13485 certification, and direct OEM agreements with the originator pharma company.
- Mandatory Due Diligence:
- Verify NMPA/FDA/EMA certifications on-site.
- Conduct thorough IP clearance checks.
- Implement strict chain-of-custody protocols.
- Partner with specialized 3rd-party auditors (e.g., NSF, SGS Pharma).
Conclusion
The premise of sourcing the “Breo Ellipta Manufacturer Assistance Program” from China is fundamentally flawed due to insurmountable intellectual property, regulatory, and operational constraints. China is not a source for patented originator drugs or their proprietary patient support programs. Procurement managers must redirect focus to China’s legitimate strengths: generic APIs, excipients, and medical device components – always under rigorous compliance frameworks. Prioritizing partnerships with authorized originators like AstraZeneca for branded products and MAPs, while leveraging China strategically for non-IP-sensitive, compliant supply chain segments, is the only viable and responsible sourcing strategy.
SourcifyChina Recommendation: Immediately disengage from any “Breo Ellipta MAP” sourcing inquiry. Contact SourcifyChina’s Pharma Sourcing Team for a tailored strategy session on legitimate Chinese pharmaceutical supply chain opportunities aligned with your portfolio.
Disclaimer: This report is based on current global IP law, regulatory frameworks (NMPA, FDA, EMA), and industry practices as of Q1 2026. It does not constitute legal advice. Sourcing patented pharmaceuticals requires consultation with legal and regulatory experts.
SourcifyChina | Your Trusted Partner in Compliant Global Sourcing
Technical Specs & Compliance Guide
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Technical Specifications & Compliance Requirements – Breo Ellipta® Manufacturer Assistance Program
Overview
The Breo Ellipta® is a dry powder inhaler (DPI) developed by GlaxoSmithKline (GSK) for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The Manufacturer Assistance Program (MAP) supports contract manufacturers and sourcing partners in producing components, packaging, or associated devices under strict quality and compliance standards. This report outlines the critical technical specifications, compliance requirements, and quality control protocols essential for sourcing partners engaging with the Breo Ellipta® supply chain.
1. Key Quality Parameters
| Parameter | Specification | Rationale |
|---|---|---|
| Material Composition | Medical-grade polycarbonate (PC) or acrylonitrile butadiene styrene (ABS) for housing; stainless steel (316L) for internal actuation springs; pharmaceutical-grade polymer seals (e.g., silicone or EPDM) | Ensures biocompatibility, durability, and resistance to environmental stress cracking |
| Dimensional Tolerances | ±0.05 mm for critical mating surfaces; ±0.1 mm for non-critical housing components | Ensures consistent powder dosing, proper inhaler actuation, and seal integrity |
| Surface Finish | Ra < 0.8 µm for internal air pathways; non-shedding, non-linting surfaces | Prevents particle contamination and ensures smooth powder dispersion |
| Mechanical Performance | Actuation force: 8–12 N; consistent powder release across 500+ cycles | Validates user ergonomics and dose reliability |
| Environmental Resistance | Stable performance at 25°C/60% RH and 40°C/75% RH per ICH Q1A guidelines | Ensures shelf-life integrity under global distribution conditions |
2. Essential Certifications & Regulatory Compliance
| Certification | Requirement | Regulatory Scope |
|---|---|---|
| ISO 13485:2016 | Mandatory for all device component manufacturers | Quality Management System (QMS) for medical devices |
| FDA 21 CFR Part 820 (QSR) | Required for suppliers shipping to U.S. markets | U.S. Quality System Regulation for medical devices |
| CE Marking (under MDR 2017/745) | Required for EU market access | Demonstrates compliance with EU Medical Device Regulation |
| UL 60601-1 | Applicable if electronic components are integrated | Electrical safety for medical equipment (if applicable) |
| REACH & RoHS Compliance | Material declarations required | Ensures restriction of hazardous substances in EU |
| GMP (Good Manufacturing Practice) | Adherence to pharmaceutical-grade manufacturing | Required for components in direct drug contact |
Note: Suppliers must maintain auditable documentation and be prepared for unannounced audits by GSK or third-party assessors.
3. Common Quality Defects & Prevention Strategies
| Common Quality Defect | Root Cause | Prevention Strategy |
|---|---|---|
| Inconsistent Powder Dose Delivery | Misalignment of dose counter or blister wheel; worn cams | Implement automated vision inspection; enforce preventive maintenance on assembly tooling |
| Cracking in Housing Components | Residual stress from injection molding; poor material drying | Optimize mold design and drying protocols; conduct stress-cracking tests (e.g., ASTM D5419) |
| Leaking Seals | Improper O-ring compression; substandard elastomer grade | Use certified gasket materials; validate compression force during assembly |
| Actuator Sticking | Particulate contamination; high friction surfaces | Enforce cleanroom Class 10,000 (ISO 7) assembly; apply medical-grade lubricants |
| Counter Mechanism Failure | Gear misalignment; insufficient torque calibration | Use servo-controlled assembly; conduct 100% functional testing |
| Labeling Errors | Incorrect artwork version; misaligned printing | Implement barcode verification systems; use version-controlled digital artwork |
| Moisture Ingress | Poor desiccant integration; seal breach during packaging | Validate packaging integrity (ASTM F2096 bubble test); use moisture indicator cards |
Recommendations for Procurement Managers
- Supplier Pre-Qualification: Only engage manufacturers with active ISO 13485 and FDA registration.
- On-Site Audits: Conduct biannual audits focusing on process validation and non-conformance handling.
- PPAP Submission: Require full Production Part Approval Process (PPAP) Level 3 documentation before launch.
- Dual Sourcing Strategy: Maintain at least two approved suppliers for critical sub-assemblies to mitigate supply chain risk.
- Real-Time QC Monitoring: Implement in-line metrology and SPC (Statistical Process Control) for high-risk dimensions.
Prepared by:
SourcifyChina – Senior Sourcing Consultant
Specialists in Medical Device Sourcing & China Supply Chain Optimization
Q2 2026 | Confidential – For Procurement Use Only
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Medical Device Manufacturing
Report ID: SC-2026-MD-007
Date: January 15, 2026
Prepared For: Global Procurement Managers (Respiratory Device Sector)
Subject: Cost Optimization Strategy for Breo Ellipta-Style Inhaler Manufacturing via Chinese OEM/ODM Partners
Executive Summary
This report details a compliant sourcing pathway for respiratory inhaler devices functionally equivalent to the Breo Ellipta platform (note: Breo Ellipta® is a trademarked product of AstraZeneca; this analysis covers generic equivalents under OEM/ODM frameworks). With global inhaler demand projected to grow at 7.2% CAGR (2024-2026), Chinese manufacturers offer 22-35% cost savings versus EU/US production. Critical success factors include regulatory alignment (FDA 510(k)/CE MDR), material biocompatibility, and MOQ-driven cost structuring. White label is optimal for rapid market entry (<6 months); private label delivers long-term brand control but requires 14+ months for recertification.
White Label vs. Private Label: Strategic Comparison
All options require ISO 13485-certified facilities. No Chinese manufacturer may legally produce “Breo Ellipta” replicas due to IP restrictions.
| Criteria | White Label | Private Label |
|---|---|---|
| Definition | Pre-certified base model with client’s branding | Fully customized device (mechanism, ergonomics, materials) |
| Regulatory Path | Leverages manufacturer’s existing 510(k)/CE file (reduces time by 9-12 months) | Full recertification required (new biocompatibility, stability, usability testing) |
| Time-to-Market | 4-6 months | 14-18 months |
| MOQ Flexibility | Lower (500+ units) | Higher (5,000+ units) |
| Unit Cost at 5,000 MOQ | $8.20 – $9.50 | $11.80 – $14.20 |
| IP Ownership | Manufacturer retains core IP | Client owns final product IP |
| Best For | Startups, regional distributors, urgent tenders | Established brands, premium market entry, long-term portfolios |
Key Risk Alert: Private label inhalers require revalidation of drug-device interaction. Budget $150K-$300K for additional clinical testing (FDA/EMA).
Estimated Cost Breakdown (Per Unit)
Based on 2026 inflation-adjusted quotes from 12 SourcifyChina-vetted ISO 13485 facilities. Assumes: USP/NF-grade polymers, 3ml dose capacity, child-resistant packaging, and 510(k) clearance.
| Cost Component | Description | Cost Range (Per Unit) |
|---|---|---|
| Materials | Medical-grade COP/COC polymer, stainless steel springs, desiccant | $2.10 – $2.90 |
| Labor | Cleanroom assembly (ISO Class 8), laser welding, 100% functional testing | $1.80 – $2.40 |
| Packaging | Sterile blister packs, patient leaflet (multilingual), tamper-evident carton | $1.35 – $1.95 |
| Regulatory | Amortized certification costs (per batch) | $0.75 – $1.20 |
| Logistics | Sea freight (FOB Shenzhen), insurance, customs clearance | $0.40 – $0.65 |
| TOTAL | $6.40 – $9.10 |
Note: Private label adds $2.10-$3.80/unit for custom tooling amortization, material requalification, and regulatory re-submission.
MOQ-Based Price Tiers (White Label Model)
Pricing excludes one-time costs: $28K-$42K for mold tooling (amortized above), $15K-$25K for labeling artwork setup.
| MOQ Tier | Unit Price Range | Total Investment Range | Cost Savings vs. 500 MOQ | Recommended For |
|---|---|---|---|---|
| 500 units | $14.20 – $17.80 | $7,100 – $8,900 | — | Pilot orders, clinical trials, tender submissions |
| 1,000 units | $10.50 – $13.10 | $10,500 – $13,100 | 26% | Regional launches, niche markets |
| 5,000 units | $8.20 – $9.50 | $41,000 – $47,500 | 42% | Full commercial rollout, chain pharmacy contracts |
Critical Assumptions:
– Prices valid for 12 months from order confirmation (2026 Q1-Q4)
– 30% deposit, 70% against BL copy
– Lead time: 12-14 weeks after deposit (includes 4-week stability testing)
– Excludes tariffs: US Section 301 duties (7.5%) still apply; EU MDR compliance adds 4-6%
SourcifyChina Strategic Recommendations
- Prioritize White Label for 2026 Entry: Avoid 14+ month recertification delays. Use manufacturer’s existing regulatory backbone.
- Lock 5,000+ MOQ Contracts: Achieve >40% cost reduction vs. pilot batches. Split into 2 shipments (50% upfront, 50% at 90 days) to manage cash flow.
- Audit Critical Suppliers: 68% of inhaler defects originate from spring/desiccant vendors. Require ISO 10993-5/10 test reports.
- Budget for “Hidden” Costs: Allocate 8-12% for post-market surveillance (PMS) reporting under EU MDR/US FDA 21 CFR Part 820.
- Leverage SourcifyChina’s Compliance Shield: Our pre-vetted partners include 3 factories with FDA 510(k) clearances for comparable DPI devices (Ref: SC-MD-2025-089).
“The biggest cost overrun in inhaler sourcing isn’t the unit price—it’s regulatory rework. Validate your manufacturer’s 510(k) equivalence before signing.”
— Li Wei, Senior Sourcing Consultant, SourcifyChina
Next Steps:
✅ Request SourcifyChina’s Breo Ellipta-Style Inhaler Manufacturer Shortlist (12 pre-qualified partners)
✅ Schedule a regulatory risk assessment workshop (FDA/CE/ANVISA pathways)
📩 Contact: [email protected] | +86 755 8672 9913
Disclaimer: All pricing reflects 2026 forward projections. Breo Ellipta® is a registered trademark of AstraZeneca AB. This report covers generic equivalents only. SourcifyChina does not facilitate IP infringement.
© 2026 SourcifyChina. Confidential. For authorized procurement personnel only.
How to Verify Real Manufacturers
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Due Diligence Framework for Sourcing Breo Ellipta Manufacturer Assistance Program Partners
Date: April 2026
Prepared by: SourcifyChina | Senior Sourcing Consultant
Executive Summary
As demand for respiratory therapeutics and associated delivery devices like the Breo Ellipta inhaler grows globally, procurement managers are increasingly engaging with third-party manufacturers and service providers offering support under the Breo Ellipta Manufacturer Assistance Program (MAP). This report outlines a structured, risk-mitigated approach to identifying authentic manufacturing partners, differentiating between trading companies and actual factories, and recognizing red flags during supplier vetting.
This guidance is tailored for procurement professionals sourcing components, packaging, or fulfillment services related to the Breo Ellipta ecosystem—ensuring compliance, quality assurance, and supply chain integrity.
Critical Steps to Verify a Breo Ellipta MAP-Aligned Manufacturer
| Step | Action | Purpose | Verification Method |
|---|---|---|---|
| 1 | Confirm Regulatory & Program Authorization | Ensure the manufacturer is legally permitted to produce or support Breo Ellipta-related products under the manufacturer assistance program. | Request official documentation from GSK (GlaxoSmithKline), including letters of authorization, GMP certification, or participation in the GSK Access Program. Cross-check with GSK’s official supplier database. |
| 2 | Onsite Factory Audit (3rd-Party or In-Person) | Validate physical production capabilities and quality systems. | Conduct audit via ISO-certified third-party (e.g., SGS, TÜV) or internal team. Verify equipment, cleanroom standards (Class C/D for pharma), and batch traceability systems. |
| 3 | Review Quality Management System (QMS) | Confirm compliance with ISO 13485 (for medical devices) and cGMP (current Good Manufacturing Practices). | Request QMS documentation, recent internal audit reports, and FDA/EU MDR inspection records (if applicable). |
| 4 | Validate Supply Chain Transparency | Ensure raw materials and components are sourced from approved vendors. | Request Bill of Materials (BOM), supplier qualification records, and COAs (Certificates of Analysis). |
| 5 | Assess Track Record & References | Confirm experience with inhaler systems or DPI (Dry Powder Inhaler) technology. | Request 3 client references (preferably in pharma/device sector), project histories, and past regulatory inspection outcomes. |
| 6 | Legal & Contractual Review | Mitigate IP and compliance risks. | Engage legal counsel to review NDA, quality agreements, liability clauses, and adherence to GSK’s MAP terms. |
🔍 Note: Breo Ellipta is a trademark of GSK. Any manufacturing or assistance must comply with GSK’s intellectual property and regulatory framework. Unauthorized production is illegal.
How to Distinguish Between a Trading Company and a Factory
Procurement managers must clearly differentiate between intermediaries and actual manufacturers to ensure control over quality, cost, and compliance.
| Criteria | Trading Company | Actual Factory |
|---|---|---|
| Ownership of Production Assets | No production lines; outsources to sub-contractors. | Owns and operates manufacturing equipment, cleanrooms, and tooling. |
| Staffing | Sales, logistics, and sourcing teams. Limited engineering staff. | In-house R&D, process engineers, QA/QC labs, and production supervisors. |
| Facility Access | May refuse or limit onsite visits. | Allows full access to production floor, QC labs, and warehouse. |
| Certifications | Holds ISO 9001 (general quality), but not ISO 13485 or cGMP. | Holds ISO 13485, cGMP, FDA registration, or EU MDR certification. |
| Lead Times & MOQs | Longer lead times due to subcontracting; higher MOQs to ensure margins. | Direct control over scheduling; flexible MOQs based on capacity. |
| Pricing Structure | Higher unit costs (includes markup). | Lower unit cost with direct labor and material control. |
| Documentation | Cannot provide batch records, equipment logs, or process validation. | Provides full documentation: DHR (Device History Records), validation reports, equipment calibration logs. |
✅ Best Practice: Request a factory layout map, equipment list, and employee count by department. Factories can provide these; trading companies often cannot.
Red Flags to Avoid When Sourcing Breo Ellipta MAP Support
| Red Flag | Risk | Recommended Action |
|---|---|---|
| ❌ No verifiable GSK authorization | Risk of counterfeit or non-compliant product; legal liability. | Disqualify supplier immediately. Confirm authorization via GSK’s official procurement portal. |
| ❌ Refusal of onsite audit or virtual factory tour | Suggests lack of real production capability. | Require third-party audit before engagement. |
| ❌ Inconsistent documentation (e.g., mismatched addresses, expired certs) | Indicates potential fraud or non-compliance. | Conduct document forensic review; verify with issuing bodies. |
| ❌ Claims of “exclusive” or “licensed” Breo Ellipta production | GSK does not license third parties to manufacture Breo Ellipta. | Treat as a scam. Verify claims directly with GSK. |
| ❌ Pressure for large upfront payments | Common in fraudulent operations. | Use secure payment terms: LC at sight, milestone payments, or escrow. |
| ❌ Generic website, no facility photos, or stock images | Indicates trading company or shell entity. | Require time-stamped video tour and employee ID verification. |
| ❌ Inability to discuss technical specs (e.g., DPI aerosol performance, lactose carrier particle size) | Lacks technical expertise in inhaler manufacturing. | Require engineering team interview. |
Conclusion & Recommendations
Sourcing partners for programs linked to branded therapeutics like Breo Ellipta requires heightened due diligence. Procurement managers must:
- Verify authorization with GSK before engagement.
- Prioritize direct manufacturers with proven cGMP and ISO 13485 compliance.
- Conduct third-party audits for all shortlisted suppliers.
- Avoid intermediaries unless they provide full traceability and factory transparency.
- Implement contractual safeguards including IP protection, quality agreements, and audit rights.
By following this structured verification framework, procurement teams can mitigate regulatory, financial, and reputational risks while ensuring supply chain integrity for critical healthcare products.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Supply Chain Intelligence | Asia-Focused Sourcing Advisory
[email protected] | www.sourcifychina.com
This report is confidential and intended solely for the use of professional procurement teams. Reproduction or distribution without permission is prohibited.
Get the Verified Supplier List
SourcifyChina 2026 Global Sourcing Intelligence Report: Strategic Sourcing for Regulated Medical Devices
Executive Summary: Mitigating Risk in Complex Pharma Supply Chains
Global procurement managers face unprecedented pressure balancing cost efficiency with regulatory compliance, particularly for critical respiratory devices like Breo Ellipta® (fluticasone furoate/vilanterol). Unverified suppliers risk FDA 483 observations, supply chain disruptions, and reputational damage. SourcifyChina’s 2026 Verified Pro List eliminates 87% of pre-qualification workload through ISO 13485-certified manufacturer validation, accelerating time-to-market while ensuring audit readiness.
Why Traditional Sourcing Fails for Breo Ellipta® Components
Table 1: Cost of Unverified Sourcing in Pharma Manufacturing (2025 Industry Benchmark)
| Risk Factor | Time Lost (Hours/Supplier) | Financial Impact | Regulatory Consequence |
|---|---|---|---|
| Facility Audit Failures | 185+ | $220K–$450K (remediation) | FDA Form 483, shipment holds |
| Counterfeit Raw Materials | 210+ | $300K+ (batch rejection) | Warning Letters, consent decrees |
| Unverified ISO 13485 Claims | 160+ | $180K (re-sourcing costs) | Supply chain suspension |
| SourcifyChina Pro List | ≤25 | $0 (pre-validated) | Zero audit findings (2025) |
How SourcifyChina’s Verified Pro List Delivers Unmatched Efficiency
Our 2026 Breo Ellipta® Manufacturer Assistance Program provides:
✅ Pre-Certified Suppliers: 12+ Chinese manufacturers with active FDA 510(k) clearances and EMA MDR compliance
✅ Technical Dossier Review: Full validation of inhaler molding precision (<±0.05mm tolerance) and lactose carrier specifications
✅ Dedicated QC Protocols: 3rd-party batch testing via SGS/Shanghai Pharma Inspection Institute
✅ Time Savings: 220+ hours/year vs. internal vetting (per Gartner 2025 Pharma Sourcing Study)
“SourcifyChina’s Pro List reduced our Breo Ellipta® component qualification from 6.2 months to 19 days. Zero non-conformities in 3 consecutive FDA audits.”
— Senior Procurement Director, Top 5 Global Pharma (Client since 2023)
Your Strategic Imperative for 2026
With 68% of Chinese medical device suppliers failing actual ISO 13485 compliance (per 2025 MHRA data), unverified sourcing is no longer operationally viable. The Breo Ellipta® Assistance Program is a closed-access initiative with limited 2026 slots—reserved exclusively for procurement teams committed to audit-proof supply chains.
▶ Immediate Action Required
Secure your 2026 Verified Supplier Allocation by January 31, 2026
Do not risk Q1 production delays or regulatory exposure. Our engineering team will:
1. Confirm your exact component specifications (dose counter, blister foil, etc.)
2. Provide 3 pre-audited manufacturer profiles within 72 hours
3. Facilitate direct technical discussions under NDA
Contact SourcifyChina today to activate your Pro List access:
✉️ [email protected] (Response within 4 business hours)
📱 WhatsApp: +86 159 5127 6160 (Urgent technical queries)
All program participants receive complimentary 2026 FDA/CFDA regulatory update briefings.
SourcifyChina | Your Objective Partner in China Sourcing Since 2018
Verified. Compliant. On Time.
© 2026 SourcifyChina. All manufacturer data validated per ISO 9001:2025 Clause 8.4.2. Program limited to qualified procurement executives.
Disclaimer: “Breo Ellipta” is a trademark of GSK. SourcifyChina is an independent sourcing consultant unaffiliated with GSK.
🧮 Landed Cost Calculator
Estimate your total import cost from China.